Special Podcast Episodes

Oncology Data Advisor: Welcome to Oncology Data Advisor. Today I'm here with Dr. Ash Alpert. Thank you so much for joining us. Ash Alpert, MD, MFA: I'm Dr. Ash Alpert. I'm a postdoctoral fellow in health services research at Brown University, and I'm a hematologist and medical oncologist. My research focuses on improving the experiences and outcomes of transgender people with cancer. Oncology Data Advisor: Would you like to tell us a little bit about the two posters that you presented at ASCO re...
Oncology Data Advisor: Welcome to Oncology Data Advisor. I am here with Dr. Ian Krop of Yale University who presented data on the novel HER3-targeting antibody-drug conjugate patritumab deruxtecan in HER3-expressing metastatic breast cancer. Thank you for joining us, Dr. Krop. Ian Krop, MD, PhD: I'm happy to be here. And just so you know, we all call it just HER3-DXd, which is a lot easier to say than patritumab deruxtecan. Oncology Data Advisor: Thank you. Why is there so much excitement about ...
Oncology Data Advisor: Hi, welcome to Oncology Data Advisor. I'm Beth Heller, and I'm here with Dr. London from the Dana-Farber Cancer Institute and Boston Children's Hospital. She is presenting her research at the ASCO 2022 Annual Meeting. Dr. London, can you please tell us a bit about your research? Wendy London, PhD: Yes, I'd be happy to. Thank you very much for inviting me to come in and talk to you today. I am an Associate Professor of Pediatrics at Harvard Medical School, and I began worki...
Oncology Data Advisor: Welcome to Oncology Data Advisor, I'm Keira Smith. Today, I'm here at the ASCO Annual Meeting in Chicago speaking with Jason Mouabbi from MD Anderson Cancer Center. Thank you so much for joining us today. Jason Mouabbi, MD: Thank you, happy to be here. Oncology Data Advisor: Would you like to tell us a little bit about your poster here? Dr. Mouabbi: Yes, sure. At MD Anderson, I'm responsible for lobular breast cancer. I'm an expert in that field. Recently, we have shown in...
Oncology Data Advisor: Welcome to Oncology Data Advisor, I'm Keira Smith. Today, I'm here at the ASCO Annual Meeting in Chicago, speaking with Megan-Claire Chase of SHARE Cancer Support. Megan-Claire, thank you so much for being with us today. Megan-Claire Chase: Thank you so much. I'm so excited. Oncology Data Advisor: So, would you like to tell us a little bit about your story? Ms. Chase: Yes. So, my story begins like this; I always knew I would get cancer, and that's not because I'm a pessimi...
Oncology Data Advisor: Welcome to Oncology Data Advisor, I'm Keira Smith. Today, I'm here at the ASCO Annual Meeting in Chicago, speaking with Urvi Shah from Memorial Sloan Kettering Cancer Center (MSKCC). Thank you for joining us. Would you like to tell us a little bit about yourself? Urvi Shah, MD: Sure. I'm a Hematologist and Oncologist on the Myeloma Service at Memorial Sloan Kettering Cancer Center. I'm happy to be here to talk to you all. Oncology Data: I know you moderated the poster disc...
Oncology Data Advisor™ · Exploring the Impact of Cemiplimab and Pembrolizumab in Cutaneous Squamous Cell Carcinoma In honor of Melanoma Awareness Month, Oncology Data Advisor spoke with Dr. Shaheer Khan, an Assistant Professor of Medicine at Columbia University Irving Medical Center. Dr. Khan shares the promising results of two recent trials of cemiplimab and pembrolizumab for cutaneous squamous cell carcinoma, explains future directions in the treatment of patients who are ineligib...
Maria Badillo, MSN, RN, OCN®, CCRP: Good afternoon, Sherry. How are you doing? Sherry Adkins, MSN, APN-C: Great, Maria. How are you? Ms. Badillo: I'm good. Happy Nurses Week. Ms. Adkins: Thank you, you too. Ms. Badillo: Before we start our interview, I would like to give you a little background about Sherry. Sherry is an advanced practice nurse with over 20 years of experience. She completed her advanced practice oncology fellowship at the University of Texas Health Sciences 14 years ago, and th...
Oncology Data Advisor™ · Taking a Nuanced Approach to Testicular Cancer Management With Sam Kaffenberger, MD For this interview in honor of Testicular Cancer Awareness Month, Dr. Sam Kaffenberger, an Assistant Professor of Urology at the University of Michigan Health System, explains the importance of taking a nuanced approach to the management of individual patients with testicular cancer, with the goal of minimizing toxicity and achieving the best possible outcomes for treatment a...
Oncology Data Advisor™ · Can Digital Health Tools Improve Quality of Life in Multiple Myeloma? In this interview in honor of Multiple Myeloma Awareness Month, Dr. Rahul Banerjee, a Clinical Fellow in Medicine at the University of California, San Francisco, and member of the Oncology Data Advisor Editorial Board, speaks with Dr. Neha Korde of Memorial Sloan Kettering Cancer Center about the potential of digital health tools to improve quality of life for patients with multiple myelom...
Oncology Data Advisor™ · Exploring Recent Advances in Testicular Cancer Surgery and Access to Care This interview in honor of Testicular Cancer Awareness Month features Dr. Andrew Winer, Chief of Urology at Kings County Hospital in New York. Dr. Winer discusses the ongoing research regarding new approaches for testicular cancer surgery, strategies to address disparities in health care access for underserved populations, and the importance of taking a multidisciplinary approach to ac...
Oncology Data Advisor™ · Personalizing the Approach to Testicular Cancer Management With Aditya Bagrodia, MD, FACS This interview in honor of Testicular Cancer Awareness Month features Dr. Aditya Bagrodia, an Associate Professor of Urology at the University of California, San Diego. Dr. Bagrodia explains the factors that should be considered when selecting treatment options—including surgery, chemotherapy, radiation, or surveillance—for patients with testicular cancer, the future of...
Oncology Data Advisor™ · Considering VTE Risk Factors and Prophylaxis in Myeloma: Rajshekhar Chakraborty and Rahul Banerjee In this interview in honor of Multiple Myeloma Awareness Month, Dr. Rahul Banerjee, a Clinical Fellow in Medicine at the University of California, San Francisco, and member of the Oncology Data Advisor Editorial Board, speaks with Dr. Rajshekhar Chakraborty of Columbia University Irving Medical Center about risk factors for the development of venous thromboembo...
Oncology Data Advisor™ · Can Diet and Nutrition Impact Multiple Myeloma Outcomes? Urvi Shah and Rahul Banerjee In honor of Multiple Myeloma Awareness Month, Dr. Rahul Banerjee, a Clinical Fellow in Medicine at the University of California, San Francisco, and member of the Oncology Data Advisor editorial board, speaks with Dr. Urvi Shah about the importance of ensuring proper diet and nutrition, as well as the impact of the microbiome, for patients with multiple myeloma. Rahul Banerj...
Oncology Data Advisor™ · The Groundbreaking Approval of Tebentafusp for Uveal Melanoma With Richard Carvajal, MD Recently, the FDA granted approval to tebentafusp for the treatment of patients with human leukocyte antigen (HLA)-A*02:01–positive unresectable or metastatic uveal melanoma, marking the first agent to be approved for this rare ocular malignancy. In this interview, Dr. Richard Carvajal, Associate Professor of Medicine at Columbia University Irving Medical Center and edito...
Oncology Data Advisor™ · Advocating for Patients in Multiple Myeloma Clinical Trials: Manni Mohyuddin and Rahul Banerjee In this interview in honor of Multiple Myeloma Awareness Month, Dr. Rahul Banerjee, a Clinical Fellow in Medicine at the University of California, San Francisco, and member of the Oncology Data Advisor editorial board, speaks with Dr. Manni Mohyuddin about the importance of designing clinically relevant end points for clinical trials in multiple myeloma. Rahul Ban...
Oncology Data Advisor: Welcome to Oncology Data Advisor. Today I'm here with Dr. Augusto Villanueva. Thank you so much for joining us today. Augusto Villanueva, MD, PhD: It's great to be here with you. Oncology Data Advisor: Could you tell us a little bit about what you do at Mount Sinai? Dr. Villanueva: I'm a hepatologist by training, but I've been doing research in HCC for the last 15 years, focusing on biomarker development, early detection, biomarkers of treatment response, and using liquid ...
This interview has been conducted in partnership with AAMDSIF, the world's leading nonprofit health organization dedicated to supporting patients and families living with aplastic anemia, MDS, paroxysmal nocturnal hemoglobinuria, and related bone marrow failure diseases. The Foundation provides answers, support, and hope to thousands of patients and their families around the world. Oncology Data Advisor: Welcome to Oncology Data Advisor. In honor of Rare Disease Day, I'm here today with Dr. Amy ...
Oncology Data Advisor: Hi, everyone. Thank you so much for joining us. Today we're here in honor of World Cancer Day with our Editor in Chief, Dr. Thomas Abrams, who is an Assistant Professor of Medicine at Harvard Medical School, as well as two of our editorial board members, Dr. Ulka Vaishampayan, a Professor of Medicine at the University of Michigan Rogel Cancer Center, and Beth Sandy, an outpatient thoracic oncology nurse practitioner at the University of Pennsylvania Abramson Cancer Center....
Oncology Data Advisor: Welcome to Oncology Data Advisor. Today I'm here with Dr. Kelly Brassil of the University of Texas MD Anderson Cancer Center and Dr. Rahul Banerjee from the University of California, San Francisco. Rahul Banerjee, MD: Thank you for having us. As we'll talk about, this is a really exciting area of research interplay between digital health supportive care and bone marrow transplantation, but it's not the traditional route of research that a lot of institutions engage upon. I...
Oncology Data Advisor: Welcome to Oncology Data Advisor. Today I'm here with Dr. Thomas Abrams, our Editor in Chief. Dr. Abrams, thank you so much for joining us today. Thomas Abrams, MD: It's my pleasure. Oncology Data Advisor: So can you give us an overview of the COSMIC-021 trial and the results that your team found? Dr. Abrams: Sure. This is a very preliminary trial. It's one cohort of a larger multicancer trial looking at a specific pair of drugs. One drug is called cabozantinib, which is a...
Oncology Data Advisor: I'm Keira Smith with Oncology Data Advisor. Today I'm here with Dr. Matthew Davids. Matthew Davids, MD, MMSc: Hello, I'm Matthew Davids. I'm an Associate Professor of Medicine at Harvard Medical School, and I direct the Clinical Research Program in the Division of Lymphoma at Dana-Farber Cancer Institute in Boston. Oncology Data Advisor: When a patient is told they have a p53 mutation and they ask you about p53 biology, what are some of the most important points to counsel...
Oncology Data Advisor: Welcome to Oncology Data Advisor. Today I'm here with Dr. Sumit Gupta. By way of background, why is research in racial, ethnic, and socioeconomic health disparities important? Sumit Gupta, MD: I think there's been an increasing awareness over, well, decades, but it's reached more prominence in recent times—in general, disparities in all of those parameters in medicine. I think there are areas of medicine such as childhood ALL where we are fortunate that we actually do pret...
Oncology Data Advisor: Welcome to Oncology Data Advisor. Today I'm here with Dr. Brigid Killelea. Brigid Killelea, MD, FACS: Hi, my name is Brigid Killelea. I am a breast surgical oncologist. I focus my practice on patients with benign and malignant breast disease. This includes women who have breast cancer; women who are at high risk for breast cancer, either because of their own history or family history; and those that have benign diseases of the breast. I practice in Bridgeport, Connecticut,...
Oncology Data Advisor: Welcome to Oncology Data Advisor. I'm here today with Dr. Richard Zelkowitz. Dr. Zelkowitz, could you tell us a little bit about what you do at Hartford HealthCare? Richard Zelkowitz, MD: I've been in town for about 32 years. I came in 1989, and my practice has been limited to breast cancer for probably 20 to 25 years. I'm a clinician, so most of what I do is clinical work. I'm very interested in clinical research and putting people on trials. I have seen a lot in 30 years...
Welcome to Oncology Data Advisor. For this live panel discussion in honor of breast cancer awareness month, I'm here today with Christine Samuel, an advanced practice provider at MD Anderson Cancer Center; Mikel Ross, a nurse practitioner at Memorial Sloan Kettering Cancer Center; and Lillie Shockney, a Professor of Surgery at Johns Hopkins University. Thank you all for joining us. We're excited to have a great discussion today. Oncology Data Advisor: Hi, everyone. Welcome to Oncology Data Advis...
This interview has been conducted in partnership with the National Breast Cancer Foundation (NBCF). Recognized as one of the leading breast cancer organizations in the world, NBCF is Helping Women Now® by providing early detection, education, and support services to those affected by breast cancer. A recipient of Charity Navigator's highest 4-star rating for 14 years, NBCF provides support through their National Mammography Program, Patient Navigation, breast health education, and patient suppor...
Oncology Data Advisor™ · Breast Cancer and Pandemic Challenges With Lillie Shockney, RN, BS, MAS, HON-ONN-CG Although the management of breast cancer has been impacted by the COVID-19 pandemic, the cancer care team has developed strategies to optimize screening and treatment experiences in spite of these challenges. In this interview, Lillie Shockney, RN, BS, MAS, HON-ONN-CG, Professor of Surgery at Johns Hopkins University and member of the National Breast Cancer Foundation Medical...
This interview has been conducted in partnership with the National Breast Cancer Foundation (NBCF). Recognized as one of the leading breast cancer organizations in the world, NBCF is Helping Women Now® by providing early detection, education, and support services to those affected by breast cancer. A recipient of Charity Navigator's highest 4-star rating for 14 years, NBCF provides support through their National Mammography Program, Patient Navigation, breast health education, and patient suppor...
This interview has been conducted in partnership with the National Breast Cancer Foundation (NBCF). Recognized as one of the leading breast cancer organizations in the world, NBCF is Helping Women Now® by providing early detection, education, and support services to those affected by breast cancer. A recipient of Charity Navigator's highest 4-star rating for 14 years, NBCF provides support through their National Mammography Program, Patient Navigation, breast health education, and patient suppor...
This interview has been conducted in partnership with the National Breast Cancer Foundation (NBCF). Recognized as one of the leading breast cancer organizations in the world, NBCF is Helping Women Now® by providing early detection, education, and support services to those affected by breast cancer. A recipient of Charity Navigator's highest 4-star rating for 14 years, NBCF provides support through their National Mammography Program, Patient Navigation, breast health education, and patient suppor...
This interview has been conducted in partnership with the National Breast Cancer Foundation (NBCF). Recognized as one of the leading breast cancer organizations in the world, NBCF is Helping Women Now® by providing early detection, education, and support services to those affected by breast cancer. A recipient of Charity Navigator's highest 4-star rating for 14 years, NBCF provides support through their National Mammography Program, Patient Navigation, breast health education, and patient suppor...
This interview has been conducted in partnership with the National Breast Cancer Foundation (NBCF). Recognized as one of the leading breast cancer organizations in the world, NBCF is Helping Women Now® by providing early detection, education, and support services to those affected by breast cancer. A recipient of Charity Navigator's highest 4-star rating for 14 years, NBCF provides support through their National Mammography Program, Patient Navigation, breast health education, and patient suppor...
This interview has been conducted in partnership with the National Breast Cancer Foundation (NBCF). Recognized as one of the leading breast cancer organizations in the world, NBCF is Helping Women Now® by providing early detection, education, and support services to those affected by breast cancer. A recipient of Charity Navigator's highest 4-star rating for 14 years, NBCF provides support through their National Mammography Program, Patient Navigation, breast health education, and patient suppor...
This interview has been conducted in partnership with the National Breast Cancer Foundation (NBCF). Recognized as one of the leading breast cancer organizations in the world, NBCF is Helping Women Now® by providing early detection, education, and support services to those affected by breast cancer. A recipient of Charity Navigator's highest 4-star rating for 14 years, NBCF provides support through their National Mammography Program, Patient Navigation, breast health education, and patient suppor...
Oncology Data Advisor™ · Perspectives on Metastatic and Castration-Resistant Prostate Cancer With Ulka Vaishampayan, MD Selma Khenissi, MPS: Hello, welcome to Oncology Data Advisor. I'm Selma Khenissi from i3 Health. In honor of prostate cancer awareness month, we are here today with Dr. Ulka Vaishampayan, who will be discussing issues surrounding prostate cancer. Welcome. Ulka Vaishampayan, MD: Thank you for having me on this interview. I would like to bring our problems surroundin...
This interview has been conducted in partnership with the National Breast Cancer Foundation (NBCF). Recognized as one of the leading breast cancer organizations in the world, NBCF is Helping Women Now® by providing early detection, education, and support services to those affected by breast cancer. A recipient of Charity Navigator's highest 4-star rating for 14 years, NBCF provides support through their National Mammography Program, Patient Navigation, breast health education, and patient suppor...
This podcast has been conducted in partnership with the National Breast Cancer Foundation (NBCF). Recognized as one of the leading breast cancer organizations in the world, NBCF is Helping Women Now® by providing early detection, education, and support services to those affected by breast cancer. A recipient of Charity Navigator's highest 4-star rating for 14 years, NBCF provides support through their National Mammography Program, Patient Navigation, breast health education, and patient sup...
Keira Smith: Welcome to Oncology Data Advisor. I'm Keira Smith. Today I'm here with Dr. Thomas Abrams, the new Editor in Chief of Oncology Data Advisor. Thomas Abrams, MD: My name is Tom Abrams. I'm a gastrointestinal (GI) medical oncologist at Dana-Farber Cancer Institute. I've been there since 2006, and I see patients and engage in clinical research. It's been a wonderful career for me there. I'm really excited to be Editor in Chief of Oncology Data Advisor. This is a really fantastic online j...
Keira Smith: Welcome to Oncology Data Advisor, where we explore the latest advances in cancer research and treatment. I'm Keira Smith. In this podcast, Allison Imahiyerobo, nurse practitioner at Hematology/Oncology Physicians of Englewood, will be discussing strategies to optimize the management of patients with immune thrombocytopenia. Thank you for joining us! Allison Imahiyerobo, APN: Hi Keira, my name is Alli Imahiyerobo. I'm a nurse practitioner, and I practice at Hematology Oncology Physic...
Welcome to Oncology Data Advisor, where we explore the latest advances in cancer research and treatment. I'm Keira Smith. In this podcast, Dr. Steven Horwitz from Memorial Sloan Kettering Cancer Center will be discussing recent advances in the treatment of T-cell lymphoma. Thank you for joining us, Dr. Horwitz. Steven Horwitz, MD: Hi, pleasure to be here. I'm Dr. Steven Horwitz. I'm a medical oncologist at Memorial Sloan Kettering Cancer Center. Keira Smith: What do you consider some of the most...
· Keira Smith: Welcome to Oncology Data AdvisorTM, where we explore the latest advances in cancer research and treatment. I'm Keira Smith. In this podcast, Dr. Sara Tolaney from Dana-Farber Cancer Institute will be discussing strategies for improving the management of patients with metastatic breast cancer. Thank you for joining us, Dr. Tolaney. Sara Tolaney, MD, MPH: Thanks so much for having me. I'm Sara Tolaney. I'm a breast medical oncologist at Dana-Farber Cancer Institute here in Bo...
Welcome to Oncology Data Advisor, where we explore the latest advances in cancer research and treatment. I am Selma Khenissi from i3 Health. In this podcast, Dr. Kelly Brassil, PhD, RN, from The University of Texas MD Anderson Cancer Center, will be discussing patient-reported symptom data and how it affects patient survival and quality of life. Selma Khenissi, MPS: Can you comment on how tools such as Project Patient Voice positively impact the outcomes of patients with classical Hodgkin lympho...

Copyright © 2022 Oncology Data Advisor. All rights reserved.